Avacta secures £12.5m as cancer drug pipeline hits key milestones

 Life sciences group Avacta Therapeutics has secured £12.5m from investors as it looks to push its cancer drug pipeline towards a series of potentially significant clinical milestones.

The AIM-listed company has raised the money through a placing and subscription of new shares at 68p each, giving it funding to extend its cash runway into the second quarter of 2027.

A total of 18.4 million new shares will be issued, representing around 3.9 per cent o... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...